Project information
Vliv terapeutické inhibice BCR signalizace na genovou expresi u B buněčných malignit a její prognostický a prediktivní význam
- Project Identification
- 16-29622A (kod CEP: NV16-29622A)
- Project Period
- 4/2016 - 12/2019
- Investor / Pogramme / Project type
-
Ministry of Health of the CR
- Ministry of Health Research Programme 2015 - 2022
- MU Faculty or unit
- Central European Institute of Technology
- Cooperating Organization
-
University Hospital Brno-Bohunice
- Responsible person prof. MUDr. Mgr. Marek Mráz, Ph.D.
Vliv terapeutické inhibice BCR signalizace na genovou expresi u B buněčných malignit a její prognostický a prediktivní význam
Publications
Total number of publications: 35
2019
-
B Cell Receptor Signalling Regulation by Non-coding RNAs.
Year: 2019, type: Conference abstract
-
CD20 in the context of microenvironmental interactions of malignant B cells: Implications for targeted therapy.
Year: 2019, type: Conference abstract
-
Mechanism of leukemia cell adaptation to targeted therapy in chronic lymphocytic leukemia
Year: 2019, type: Conference abstract
-
MicroRNA a regulace BCR signalizace u B buněčných malignit: Biomarkery a terapeutické implikace.
Year: 2019, type: Conference abstract
-
Nové mechanismy regulace B buněčné signalizace u leukémií a lymfomů.
Year: 2019, type: Conference abstract
-
Regulation of B Cell Receptor signalling in B cell leukemias: novel mechanisms and therapeutic implications.
Year: 2019, type: Conference abstract
-
The surprising role of microRNAs in the DNA damage and B cell receptor signalling in malignant B cells
Year: 2019, type: Conference abstract
2018
-
CD20 is a direct regulator of B-cell receptor signaling in the microenvironment of chronic lymphocytic leukemia
Year: 2018, type: Conference abstract
-
CD20 reguluje signalizaci přes B-buněčný receptor v mikroprostředí chronické lymfocytární leukémie
Year: 2018, type: Conference abstract
-
CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo
Year: 2018, type: Conference abstract